Literature DB >> 20889272

Retinoblastoma - current treatment and future direction.

Manoj V Parulekar1.   

Abstract

Retinoblastoma is the commonest primary ocular malignancy of childhood. There are two forms - heritable and non heritable. Heritable retinoblastoma is a cancer susceptibility syndrome. Presentation is in the first few years of life, sometimes in the neonatal period. Early detection and prompt treatment can give cure rates up to 95% for intraocular tumours, but extraocular disease carries a very high mortality. The diagnosis is essentially clinical and biopsy is contraindicated due to the risk of extraocular spread. Treatment requires significant multidisciplinary input, with local ophthalmic treatment, systemic chemotherapy and external beam or plaque radiotherapy, or surgery to remove the affected eye. Screening of family members is essential for early detection. Lifelong surveillance of mutation carriers is needed due to the risk of second cancers. Newer treatment modalities including intra-arterial chemotherapy have been added to the therapeutic armamentarium in recent years.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20889272     DOI: 10.1016/j.earlhumdev.2010.08.022

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  9 in total

1.  Retinoblastoma in a young adult mimicking Coats' disease.

Authors:  Zheng Zhang; Ji-Tong Shi; Ning-Li Wang; Jian-Min Ma
Journal:  Int J Ophthalmol       Date:  2012-10-18       Impact factor: 1.779

Review 2.  Management of retinoblastoma in children: current status.

Authors:  Guillermo Chantada; Paula Schaiquevich
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

3.  Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma.

Authors:  Nithya Subramanian; Jagat R Kanwar; Rupinder K Kanwar; Subramanian Krishnakumar
Journal:  Nucleic Acid Ther       Date:  2014-12-16       Impact factor: 5.486

4.  Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma.

Authors:  Saerom Choi; Jung Woo Han; Hyosun Kim; Beom Sik Kim; Dong Joon Kim; Sung Chul Lee; Chuhl Joo Lyu
Journal:  Korean J Pediatr       Date:  2013-06-21

5.  At-risk populations for osteosarcoma: the syndromes and beyond.

Authors:  George T Calvert; R Lor Randall; Kevin B Jones; Lisa Cannon-Albright; Stephen Lessnick; Joshua D Schiffman
Journal:  Sarcoma       Date:  2012-03-12

6.  Clinical, epidemiological, and therapeutic profile of patients with a retinoblastoma diagnosis experience in the Costa Rica National Children's Hospital Oncology Unit from January 2009 to December 2015.

Authors:  Jennie Chen Lo; Carlos Rodríguez; Rigoberto Monestel; Arnoldo Zúñiga
Journal:  Ecancermedicalscience       Date:  2017-07-24

7.  Risk factors for chemotherapy-induced vomiting after general anesthesia in children with retinoblastoma: a retrospective study.

Authors:  Changjuan Zeng; Huifang Chen; Yanjuan Xu; Hong Ji; Na Du; Xuefei Song; Lili Hou
Journal:  Transl Pediatr       Date:  2021-11

8.  Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.

Authors:  Nithya Subramanian; Vaishnavi Raghunathan; Jagat R Kanwar; Rupinder K Kanwar; Sailaja V Elchuri; Vikas Khetan; Subramanian Krishnakumar
Journal:  Mol Vis       Date:  2012-11-22       Impact factor: 2.367

9.  pRB-Depleted Pluripotent Stem Cell Retinal Organoids Recapitulate Cell State Transitions of Retinoblastoma Development and Suggest an Important Role for pRB in Retinal Cell Differentiation.

Authors:  Agata Rozanska; Rodrigo Cerna-Chavez; Rachel Queen; Joseph Collin; Darin Zerti; Birthe Dorgau; Chia Shyan Beh; Tracey Davey; Jonathan Coxhead; Rafiqul Hussain; Jumana Al-Aama; David H Steel; Nissim Benvenisty; Lyle Armstrong; Manoj Parulekar; Majlinda Lako
Journal:  Stem Cells Transl Med       Date:  2022-04-29       Impact factor: 7.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.